Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment

Reuters11-07

Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment

Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of hepatitis C virus (HCV) infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment (SVR12) of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting® 2025, held by the American Association for the Study of Liver Diseases (AASLD) from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571017-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581888246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581888246","market":"us","top_or_hot":-1,"title":"Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of hepatitis C virus (HCV) infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment (SVR12) of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting® 2025, held by the American Association for the Study of Liver Diseases (AASLD) from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571017-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of hepatitis C virus (HCV) infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment (SVR12) of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting® 2025, held by the American Association for the Study of Liver Diseases (AASLD) from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571017-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLr7pms:1","article_id":"2581888246","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581888246","pubTimestamp":1762520438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir  and ruzasvir  for the treatment of hepatitis C virus  infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment  of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting 2025, held by the American Association for the Study of Liver Diseases  from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4007":"制药","AVIR":"Atea Pharmaceuticals, Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Atea Pharmaceuticals公布了Bemnifosbuvir和Ruzasvir丙型肝炎治疗的有希望的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"AVIR":0.9},"content_text":"Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment\n    \n\n        Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of hepatitis C virus (HCV) infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment (SVR12) of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting® 2025, held by the American Association for the Study of Liver Diseases (AASLD) from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571017-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581888246","isCrawlerRequest":true}